U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H10I3N2O4.Na
Molecular Weight 649.922
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IODAMIDE SODIUM

SMILES

[Na+].CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I

InChI

InChIKey=SJOULNBNMIRTRG-UHFFFAOYSA-M
InChI=1S/C12H11I3N2O4.Na/c1-4(18)16-3-6-8(13)7(12(20)21)10(15)11(9(6)14)17-5(2)19;/h3H2,1-2H3,(H,16,18)(H,17,19)(H,20,21);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C12H10I3N2O4
Molecular Weight 626.9322
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iodamide is an ionic monomeric iodinated radiographic contrast medium. It was used in many procedures and may be given intravenously or by other routes, for example by instillation into the bladder or uterus; it has also been used for computed tomography. It is usually given as a 24 to 65% solution of the meglumine salt, or as a mixture of the sodium and meglumine salts; solutions of the sodium salt have also been used. Iodamide is no longer marketed in the US.

Originator

Curator's Comment: In 1962 Bracco researchers develop the first original contrast agent from their in-house research, with reduced toxicity and high tolerability: iodamide.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
RENOVUE-65

Approved Use

Unknown

Launch Date

1978
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.58 g × h/L
24.75 g single, intravenous
dose: 24.75 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6.69 g × h/L
61.82 g single, intravenous
dose: 61.82 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14.02 g × h/L
9.8 g single, intravenous
dose: 9.8 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.29 h
24.75 g single, intravenous
dose: 24.75 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.02 h
61.82 g single, intravenous
dose: 61.82 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16.4 h
9.8 g single, intravenous
dose: 9.8 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
24.75 g single, intravenous
dose: 24.75 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
95%
61.82 g single, intravenous
dose: 61.82 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IODAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Diagnostic image quality of hysterosalpingography: ionic versus non ionic water soluble iodinated contrast media.
2009-07
Effects of iodinated contrast media on endothelium: An in vitro study.
2007-03
Contrast-enhanced voiding US for grading of reflux in adult patients prior to antireflux ureteral implantation.
2004-10
[The effect of diagnostic contrast media on the activity of lactate dehydrogenase in rat blood].
2002-11-27
Comparative multiclinical studies of iodamide and diatrizoate in excretory urography.
1973-01

Sample Use Guides

24% or 65%
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:30:34 GMT 2025
Edited
by admin
on Mon Mar 31 19:30:34 GMT 2025
Record UNII
CRK52426X3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Iodamide sodium [WHO-DD]
Preferred Name English
IODAMIDE SODIUM
WHO-DD  
Systematic Name English
Code System Code Type Description
SMS_ID
100000086408
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
EVMPD
SUB02725MIG
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
PUBCHEM
23695979
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
FDA UNII
CRK52426X3
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
EPA CompTox
DTXSID20143600
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
CAS
10098-82-5
Created by admin on Mon Mar 31 19:30:34 GMT 2025 , Edited by admin on Mon Mar 31 19:30:34 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY